drugset / Trial / NCT07424833
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.
Timeline
- Start
- 2026-03
- Primary completion
- 2029-12
- Completion
- 2031-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-3288 | Unknown | — | Oral |